SEC Form 4 · accession 0001493152-26-039285
Calidi Biotherapeutics, Inc. · CLDI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Corazon (Corsee) D. Sanders
Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 19, 2026 · 7:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001855485
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Options (right to buy)F1,F2 | $1.36 | Aug 17, 2026 | A | 6,000 | A | — | Aug 17, 2036 | Common Stock | 6,000 | 6,000 | D |
Explanation of responses
- F1On August 17, 2026, the Reporting Person was issued a non-qualified stock option to purchase 6,000 shares of common stock (the "Options") at an exercise price of $1.36 per share (equal to the closing price on the grant date, August 17, 2026) and shall vest, and become exercisable, in 1/12th per month installments over one year commencing on the grant date. The stock options were granted pursuant to the Issuer's non-employee director compensation policy and issued under the Issuer's 2023 Equity Incentive Plan.
- F2Does not include the stock options previously granted to the Reporting Person.